SCHEMBL11201971

SCHEMBL11201971

CCOC(=O)Cc1c[nH]c(-c2ccc(Br)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
SIRT2 Q8IXJ6 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 5/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
THRB P10828 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 3/20 0.43
MAPK1 P28482 2/20 0.43
S1PR4 O95977 1/20 0.43
S1PR1 P21453 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TARBP2 Q15633 1/20 0.43
PRMT5 O14744 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8212933 0.76 KMT2A (0.48) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL7257360 0.76 DGAT1 (0.38) MEN1KMT2ASIRT2HTTMAPT
SCHEMBL4872569 0.76 HSD17B10 (0.49) MAPTKDM4EALDH1A1THRBSMN1; SMN2
SCHEMBL11157975 0.75 MEN1 (0.62) MEN1KMT2AHTTMAPTKDM4E
SCHEMBL16115753 0.74 MAPK1 (0.49) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL12987888 0.73 CYP1A2 (0.51) MEN1KMT2AHTTMAPTALDH1A1
SCHEMBL7826351 0.73 KMT2A (0.44) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL8015267 0.73 KMT2A (0.44) MEN1KMT2AHTTKDM4EALDH1A1
SCHEMBL4733 0.71 CYP1A2 (0.55) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12764804 0.71 KMT2A (0.48) MEN1KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed
US-4379927-A Process for the preparation of imidazoleacetic acid derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1983-04-12 US disclosed
EP-0059156-A1 Process for the preparation of imidazoleacetic-acid derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1982-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM MEN1 1187/4885KMT2A 2611/4885SIRT2 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.